Sana Biotechnology Nasdaq IPO

Overview:

• Sana Biotechnology, a gene engineering firm, debuted on the Nasdaq market under the ticker SANA.
• The company offered 23.5 million common share at $25 per share, with gross proceeds expected to be $587.5 million.
• Morgan Stanley, Goldman Sachs, JP Morgan Securities and BofA Securities acted as the underwriters for the IPO.
• The IPO was the largest ever for a preclinical biotech company.

Chynna Lewis - Researcher